BNP Paribas Financial Markets
ARIA

BNP Paribas Financial Markets’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

BNP Paribas Financial Markets’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,802
Closed -$159K – 4372
2016
Q4 		$159K Sell
12,802
-1,827
-12% -$22K ﹤0.01% 2318
2016
Q3 		$200K Buy
14,629
+7,675
+110% +$77.1K ﹤0.01% 1745
2016
Q2 		$51.4K Buy
+6,954
New +$52.2K ﹤0.01% 2302
2016
Q1 		– Sell
-36,184
Closed -$226K – 3441
2015
Q4 		$226K Buy
36,184
+1,753
+5% +$11.5K ﹤0.01% 1852
2015
Q3 		$201K Buy
34,431
+20,503
+147% +$158K ﹤0.01% 1947
2015
Q2 		$115K Buy
13,928
+10,017
+256% +$88.6K ﹤0.01% 2007
2015
Q1 		$32.2K Buy
+3,911
New +$28.9K ﹤0.01% 2138
2014
Q4 		– Sell
-9,878
Closed -$53.3K – 3835
2014
Q3 		$53.3K Buy
9,878
+3,098
+46% +$18.1K ﹤0.01% 2558
2014
Q2 		$43.2K Buy
6,780
+6,575
+3,207% +$45.2K ﹤0.01% 2155
2014
Q1 		$1.49K Sell
205
-105
-34% -$818 ﹤0.01% 2752
2013
Q4 		$2.11K Buy
+310
New +$1.67K ﹤0.01% 3633

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.59% 1-Year Est. Return

BNP Paribas Financial Markets's ARIA Position: Q1 2017 in Review

BNP Paribas Financial Markets sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 12,802 shares — an estimated $159K sold.

BNP Paribas Financial Markets first reported a position in ARIA in Q4 2013 and held it in 11 quarters. The position peaked at $226K in Q4 2015. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • BNP Paribas Financial Markets reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 12,802 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $159K.
  • BNP Paribas Financial Markets first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 11 quarters.
  • BNP Paribas Financial Markets's Ariad Pharmaceuticals Inc position peaked at $226K in Q4 2015.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2017, filed 3 May 2017.